METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) DRUGS MARKET ANALYSIS

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, by Drug Class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020
Code : CMI1538
Pages :186
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Restraint

Patent expiration of currently existing MRSA drugs will lead to large revenue loss for key players due to introduction of low cost generic drugs. This is expected to have negative impact on Methicillin-resistant staphylococcus aureus drugs market growth. For instance, in December 2015, various key players such as Camber Pharmaceuticals, Mylan N.V., and Teva Pharmaceutical Industries Ltd. launched generic version of Zyvox (Linezolid) which is used to treat susceptible Gram-positive infections (for example, Staphylococcus and Streptococcus spp.).

Moreover, declining patient burden, and product recalls to treat MRSA drugs of some major companies are some of the factors that are expected to hamper the market growth over the forecast period.